To compare a novel generalized competing event (GCE) model versus the standard Cox proportional hazards regression model for stratifying elderly patients with cancer who are at risk for competing events.
Methods
We identified 84,319 patients with nonmetastatic prostate, head and neck, and breast cancers from the SEER-Medicare database. Using demographic, tumor, and clinical characteristics, we trained risk scores on the basis of GCE versus Cox models for cancer-specific mortality and all-cause mortality.
In test sets, we examined the predictive ability of the risk scores on the different causes of death, including second cancer mortality, noncancer mortality, and cause-specific mortality, using FineGray regression and area under the curve. We compared how well models stratified subpopulations according to the ratio of the cumulative cause-specific hazard for cancer mortality to the cumulative hazard for overall mortality (v) using the Akaike Information Criterion.
Results
In each sample, increasing GCE risk scores were associated with increased cancer-specific mortality and decreased competing mortality, whereas risk scores from Cox models were associated with both increased cancer-specific mortality and competing mortality. GCE models created greater separation in the area under the curve for cancer-specific mortality versus noncancer mortality (P , .001), indicating better discriminatory ability between these events. Comparing the GCE model to Cox models of cause-specific mortality or all-cause mortality, the respective Akaike Information Criterion scores were superior (lower) in each sample: prostate cancer, 28.6 versus 35. 5 versus 39.4; head and neck cancer, 21.1 versus 29.4 versus 40.2; and breast cancer, 24.6 versus 32.3 versus 50.8 .
Conclusion
Compared with standard modeling approaches, GCE models improve stratification of elderly patients with cancer according to their risk of dying from cancer relative to overall mortality.
INTRODUCTION
Competing risks settings are those in which an individual may experience multiple different events. 1 Competing events are important to recognize because they complicate the interpretation of effects on primary events of interest. [1] [2] [3] [4] [5] [6] [7] With advancing age, the risk of competing mortality for patients increases, and the benefit of intensifying treatment potentially diminishes. Improved methods for stratifying patients according to competing event risk are needed to help individualize treatment.
A common approach to risk stratification is to model variables on a combined end point, such as overall survival or event-free survival, aggregating one or more disease-specific events with death from other causes. This approach is problematic, however, when variables have opposing effects on competing events, because it is not possible to discriminate effects on primary versus competing events when these events are pooled.
2 As a result, common prognostic models applied do not efficiently distinguish patients at risk for dying of cancer versus noncancer causes, leading to suboptimal risk assessment strategies.
In contrast, competing event models can better discriminate effects of treatments and risk factors on specific events. 8 We previously developed a generalized competing event (GCE) model that better stratifies patients with endometrial cancer according to risk of death from cancer relative to overall mortality; however, this approach has not been validated in other settings. Therefore, we sought to validate the broader utility of this method by comparing risk scores derived using standard Cox proportional hazards regression models versus the GCE model in three different populations (prostate cancer, head and neck cancer (HNC), and breast cancer), all of which are subject to an appreciable risk of competing cancer and noncancer events.
METHODS

Population and Sampling Methods
This study was institutional review board approved. Using SEERMedicare database, we identified 51,713 patients with localized prostate cancer diagnosed from 2000 to 2009 and treated with definitive radiotherapy (RT), 9,677 patients with primary nonmetastatic HNC diagnosed from 1996 to 2009 and treated with RT with or without surgery and/or chemotherapy, and 22,929 patients with nonmetastatic primary breast cancer diagnosed from 2004 to 2009 and treated with mastectomy or lumpectomy with or without RT and/or chemotherapy. SEER covers 26% of the US cancer population. 9 Medicare provides health insurance for 97% of persons age $ 65 years. SEER-Medicare links registry data with claims files for beneficiaries enrolled in fee-forservice programs. We excluded patients if their cancer was diagnosed on death certificate or autopsy only or if they had incomplete data or noncontinuous Medicare part A/part B in the year preceding diagnosis. We also excluded 16,546 patients treated with radical prostatectomy because we found too few patients died of cancer (141 deaths, , 1%) to draw definitive conclusions about the impact of GCE models in this population. All patients were age . 66 years.
Main Outcomes
Cancer-specific mortality was defined as death as a result of prostate, HNC, or breast cancer, as appropriate for the context. Competing mortality was defined as either noncancer mortality or second cancer mortality. All-cause mortality was defined as death from any cause. Surviving patients were censored at last follow-up.
Statistical Analysis
First, we partitioned each sample into training and validation sets (Fig  1) , using 60%/40% random samples (without replacement). This was to optimize the tradeoff between robustness of the training sample and number of events in the test sets. Training cohorts were used to build models, whereas validation cohorts were used to compare models. In each training cohort, we used multivariable Cox regression 10 to develop risk scores for all-cause and cause-specific mortality using a standard set of covariates plus additional disease-specific covariates. Risk scores were calculated by taking the inner product of the coefficient vector with the data vector of the patient. 4, 8 For the GCE models, we performed Fine-Gray regressions 11 on both cause-specific and competing mortality as a function of the same covariates, and we computed risk scores in the same fashion, using training cohorts. Second cancer mortality and noncancer mortality events were pooled together as a single competing mortality event in the GCE risk score calculation. Covariates were retained in the final GCE model if they were significant (P , .05) in any individual regression model. We chose this cutoff to guard against overfitting in training samples (note that including fewer covariates reduces variance in the explanatory variables, attenuating the comparisons between GCE and standard models). GCE risk scores were computed by subtracting the competing mortality risk score from the cancer-specific mortality risk score. Note that GCE risk scores can take on any real value, with increasing values corresponding to an increasing ratio of cancer mortality to noncancer mortality risk (Appendix, online only). Despite concerns about the appropriateness of using Cox models for causespecific mortality, 12, 13 we chose this method for comparison because it has been widely applied for this purpose in the oncology literature. Bootstrap resampling with replacement (1,000 iterations) was used to obtain 95% CIs for the coefficients from the GCE model.
Standard covariates included age at diagnosis (continuous), sex, race (black v white/other), marital status (married v unmarried), median household income (lower v higher than mean), stage, grade, and modified Charlson comorbidity index (CCI), calculated using Medicare claims during the year preceding diagnosis.
14 For prostate cancer models, additional covariates included region (West v East v Midwest v South), type of RT (external beam RT only v RT plus brachytherapy v brachytherapy only), and prostate-specific antigen (PSA; continuous). We imputed the mean PSA value where PSA was missing (n = 18,809). Stage was grouped according to American Joint Committee on Cancer staging criteria (3rd and 6th editions), and grade was dichotomized as high (grade 3 and 4) versus intermediate and/or low (grade 1 and 2). For HNC models, additional covariates tested included anatomic subsite and postoperative RT (yes v no). Stage was dichotomized as regional versus localized, and grade was dichotomized as above. Multiple imputation with 20 iterations was performed for missing grade data, given fewer than 20% missing data (n = 1,697). No other variables were imputed. For HNC data, we performed additional analyses controlling for chemotherapy and RT technique (n = 8,920); however, these were not significant in any regression model, and, therefore, were not included in the final GCE model for HNC. For breast cancer models, additional covariates included region (West v East v Midwest v South), teaching hospital (yes v no), tumor size (, 2 cm v $ 2 cm to , 5 cm v $ 5 cm v size unknown), estrogen receptor and/or progesterone receptor status (positive v negative v unknown), sentinel lymph node biopsy (yes v no), axillary lymph node examination (yes v no), tumor laterality (left v right), surgery (mastectomy v lumpectomy), chemotherapy (yes v no), and RT technique (hypofractionated v conventional). Hypofractionated RT was defined as 13 to 24 daily fractions, and conventional RTwas defined as 25 to 36 daily fractions.
Event probabilities were calculated for the whole samples using cumulative incidence functions. 15, 16 The predictive ability of the models on the different cause of death incidences was tested in validation cohorts using the area under the curve (AUC) on the basis of receiver operating characteristics curves with competing risks. 17 We also used the Akaike Information Criterion and Bayesian Information Criterion to compare how well the risk scores stratified equally binned subgroups according to the ratio of the cumulative cause-specific hazard for cancer mortality to the cumulative hazard for all-cause mortality (v). We used the Nelson-Aalen method (ie, negative logarithm of the survival function) to estimate cumulative hazards and plotted v values for quantiles of the appropriate risk score (Appendix). Last, we performed a second resampling of the training and test sets for all three cohorts, to confirm the robustness of our conclusions. Additional details are provided in the Appendix. All tests were two tailed, and P , .05 indicated statistical significance. Data were extracted using SAS (SAS/STAT User's Guide, Version 9.3; SAS Institute, Cary, NC) and analyzed in R version 3.2.2 (www.r-project.org). We published an R package called gcerisk to facilitate GCE modeling used in this study.
RESULTS
Cancer Outcomes and Model Comparisons
Sample characteristics are provided in Appendix Tables A1 to A3 (online only). For patients with prostate cancer, the 10-year cumulative incidences of all-cause, cancer-specific, second cancer, and noncancer mortality were 40.2% (95% CI, 39.4% to 41.1%), 4.7% (95% CI, 4.3% to 5.0%), 9.4% (95% CI, 9.0% to 9.9%), and 26.2% (95% CI, 25.4% to 26.9%), respectively. Note that second cancer mortality and noncancer mortality together comprise competing mortality, so the cumulative incidence of competing mortality is the sum of their cumulative incidences (35.6%).
Compared with standard models, the effects of stage, grade, and PSA in the GCE model were in the same direction, whereas the effect estimates for age and CCI were generally opposite ( Table 1 ). All-cause mortality was increased for patients in the Midwest and Southern regions, but the effects of region were not significant in the other two models.
For patients with HNC, the 5-year cumulative incidences of allcause, cancer-specific, second cancer, and noncancer mortality were 59.3% (95% CI, 58.2% to 60.3%), 24.2% (95% CI, 23.4% to 25.1%), 15.9% (95% CI, 15.1% to 16.7%), and 19.1% (95% CI, 18.3% to 20.0%), respectively. With the GCE model, the effect estimates for stage, anatomic subsite, and postoperative RT were generally comparable to standard models. Compared with standard models, the GCE model gave more weight to female sex, suggesting a potential benefit of treatment intensification for elderly women. The GCE model suggested a null effect of age, and an opposite effect of CCI, in contrast to standard models (Table 2) .
For patients with breast cancer, the 5-year cumulative incidences of all-cause, cancer-specific, second cancer, and noncancer mortality were 20.1% (95% CI, 19.5% to 20.8%), 4.8% (95% CI, 4.5% to 5.2%), 3.1% (95% CI, 2.8% to 3.4%), and 12.2% (95% CI, 11.7% to 12.7%), respectively. With the GCE model, effect estimates for stage, grade, tumor size, and nodal examination were comparable to the Cox models in magnitude and direction, in contrast to GCE estimates for age, teaching hospital, and CCI, which were opposite of those from Cox models ( Table 3) .
Predictive Ability of Models on Cause-Specific Events
When Cox models were tested on patients with prostate cancer, increasing risk scores were associated with increased cancerspecific, second cancer, and noncancer mortality (Appendix). In contrast, the GCE risk score was associated with increased cancerspecific mortality (subdistribution hazard ratio [SDHR], 2.12; 95% CI, 1.89 to 2.37; P ,.001) and was associated with decreased second cancer mortality (SDHR, 0.88; 95% CI, 0.81 to 0.95; P , .001) and noncancer mortality (SDHR, 0.64; 95% CI, 0.60 to 0.67; P , .001). The GCE model produced a greater difference in AUC for cancer-specific and noncancer mortality (0.64 v 0.42; P , .001) than did the Cox model of all-cause mortality (0.66 v 0.67; P . .05) or cancer-specific mortality (0.72 v 0.59; P , .001). Results did not differ when we tested patients with prostate cancer with or without known PSA information.
When Cox models were tested in patients with HNC, increasing risk scores were associated with increased cancer-specific, second cancer, and noncancer mortality (Appendix). In contrast, the GCE risk score was associated with increased cancer-specific mortality (SDHR, 2.37; 95% CI, 2.09 to 2.70; P , .001) and second cancer mortality (SDHR, 1.44; 95% CI, 1.25 to 1.66; P , .001) but decreased noncancer mortality (SDHR, 0.62; 95% CI, 0.54 to 0.70; P , .001). Again, the GCE model produced a greater difference in AUC for cancer-specific and noncancer mortality (0.66 v 0.55; P , .001) than did the Cox models of all-cause mortality (0.74 v 0.71; P ..05) and cancer-specific mortality (0.75 v 0.68; P ,.001). Results were similar when we controlled for treatment or analyzed oropharynx versus nonoropharynx subpopulations separately.
When Cox models were tested in patients with breast cancer, increasing risk scores were associated with increased cancer-specific, second cancer, and noncancer mortality (Appendix). In contrast, the GCE risk score was associated with increased cancer-specific mortality (SDHR, 1.95; 95% CI, 1.71 to 2.23; P , .001) but decreased second cancer mortality (SDHR, 0.76; 95% CI, 0.65 to 0.88; P , .001) and noncancer mortality (SDHR, 0.51; 95% CI, 0.47 to 0.56; P , .001). Again, the GCE model produced a greater difference in AUC for cancer-specific and noncancer mortality (0.64 v 0.36; P ,.001) than did the Cox models of all-cause mortality (0.79 v 0.80; P ..05) and cancer-specific mortality (0.82 v 0.73; P ,.001).
Predictive Ability of Models on the Relative Hazard for Events of Interest (v)
With increasing GCE risk scores, we observed significant increases in the proportion of the hazard for overall mortality attributable to cancer (v). GCE models better stratified patients according to their risk of dying from cancer relative to other causes. In contrast, risk scores from the Cox models did not optimize the relative event composition (Fig 2) . For patients with prostate cancer, the Akaike Information Criterion was superior (lower) for GCE models versus the Cox models of cause-specific and all-cause mortality (25.3 v 31.2 v 35.3). Similar findings were observed for patients with HNC (24.1 v 26.7 v 36.6) and patients with breast cancer (12.7 v 33.2 v 41.6). The Bayesian Information Criterion was also superior for the GCE models in each of the three samples we tested: prostate, 26.2 versus 32.1 versus 36.2; HNC, 25.0 versus 27.6 versus 37.5; and breast, 13.6 versus 34.1 versus 42.5.
DISCUSSION
We validated a novel approach to improve prognostication beyond that achievable with traditional methods. Standard approaches to risk stratification typically involve characterizing patient risk of mortality, or event-free survival, and then tailoring treatment according to this risk. This is not a problem when effects of variables on specific events composing the end point are similar. However, this condition often does not hold in oncology, because the causes of cancer recurrence and/or mortality are generally different than for other causes of mortality. Traditional models are constrained, in general, because they assign a mean effect of a variable on both events of interest and competing events. In contrast, the GCE approach, which estimates the effects of a variable on specific events separately before aggregating them in a final model, better stratifies patients according to risk of dying from cancer relative to overall mortality. These findings indicate that measures used to evaluate the net benefit of therapies need not, and perhaps should not, be the same ones used for risk stratification. The GCE approach can be generalized to other competing risks settings; its potential is therefore broad. In the context of clinical research, better risk stratification will improve the ability to detect treatment benefits within subpopulations, ultimately leading to more powerful and cost-effective clinical trials.
18,19 GCE scores can also be used to better inform patients and physicians about the potential value of intensive treatment, thus leading to more personalized care. In terms of prostate cancer management, controversy still remains regarding when to observe or treat, 20 likely because of poorer quality of life associated with local therapies 21, 22 and competing mortality risk as a result of comorbidities.
23
Randomized controlled trials have shown that men with prostate cancer will not see the benefits of treatment for at least a decade. 24 As a consequence, men with less comorbidity are often not treated for high-risk prostate cancer, whereas younger men with comorbidity are overtreated for low-risk disease. 20, 25 In this setting, a widely accepted method to assess prognosis that incorporates patient health status is essential.
25
Patients with HNC with comorbidities are also at increased risk of competing mortality, 3, 4, 6, 26, 27 making the decision to treat with aggressive therapy difficult. Breast cancer studies have shown that for proper estimation of breast cancer death, risk factors associated with competing mortality should also be considered when evaluating potential treatments. 7, [28] [29] [30] To this end, numerous prediction models have been used in prostate cancer, 31 HNC, 26, 32 and breast cancer 33 research; however, such models do not directly isolate the effect of the main outcome of interest relative to overall mortality risk. Across oncology, it is imperative to determine how both cancer and noncancer risk factors contribute to risk of cancer death when risks for competing events are present. GCE models have the potential to provide patients with better-informed survivorship information on the basis of their individual health status.
Strengths of our study were the large population-based sample that provided detailed information about demographic and clinical factors and causes of death. 34 Although some predictors were not available, such as treatment details, family history, smoking history, 35 tissue biomarkers, 36 genetic information, 37-39 body mass index, reproductive status, performance status, and pathologic risk factors (eg margin status, extracapsular extension), we were still able to demonstrate better risk stratification and model performance using the GCE approach. Including more variables in the GCE models would likely accentuate the difference between the approaches. Longer follow-up data might improve model parameter selection and estimation by increasing incidences of events. We chose to use FineGray regression models in the construction of GCE risk scores to be consistent with prior studies. 8 It is also possible to generate GCE scores on the basis of Cox regression, 8 but often these approaches result in similar estimates 1 and would likely yield similar findings. In theory, the GCE approach will outperform standard methods whenever there is an appreciable incidence of competing events, sufficient variance in the explanatory variables, and low statistical dependence between competing events and events of interest. These conditions appeared to hold in the samples we examined.
In summary, we found that, compared with standard methods, GCE models better stratified patients according to their risk of cancer mortality relative to competing causes of death. Our study directly speaks to the necessity of developing patientcentered risk models, 40 which use patient-specific characteristics to identify patients likely to benefit from risky or costly therapies. 41, 42 Additional studies investigating the value of competing event models are needed, as their use would enhance personalized medical decision making and improve the efficiency of clinical trials.
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Methods
For each cancer site, we categorized patients on the basis of risk score and calculated the ratio (v) of the cumulative hazard for cancer-specific mortality (L CSM ) to the cumulative hazard for all-cause mortality(L ACM ) within strata:
v ranges from zero to one, with lower values of v indicating that the hazard of cancer-specific mortality is small relative to allcause mortality. In this situation, intensifying cancer therapy would be expected to have less benefit on overall survival because of the increased risk of mortality from noncancer causes. In contrast, for higher values of v, the cumulative hazard of cancer-specific mortality dominates, and the potential benefit of intensifying treatment is maximized. Thus, v may be viewed as a measure of the likelihood to benefit from treatment intensification within a risk group. Its derivation comes from the partitioning of an effect on all-cause mortality (u) into a weighted average of the cause-specific effects (u i ; Eq 2), for two events
[2]
Under this model, we assume proportional hazards for both the composite event and the cause-specific events, that is:
lðt; xÞ ¼ l 0 ðtÞexpðbxÞ [3] and l i ðt; xÞ ¼ l 0i ðtÞexpðb i xÞ [4] for event time t, data vector x, and a set of K mutually exclusive event types i є {1,…,K}. Because the hazard function can be represented as the sum of the K cause-specific hazard functions, it follows that: lðt; xÞ ¼ å l 0i ðtÞexpðb i xÞ :
We define: v i ðtÞ ¼ l i ðtÞ=lðtÞ ; [6] that is, v i (t) is the ratio of the cause-specific hazard for event type i to the hazard for all events, hence: lðt; xÞ=l 0 ðtÞ ¼ å v 0i ðtÞexpðb i xÞ [7] where v 0i (t) represents the value of v i (t) under baseline conditions. We may consider two event types: a (or composite set of) primary event(s) of interest, and a (or composite set of) competing event(s) (eg, cancer mortality and competing mortality). In this case, the proportional hazards assumptions imply that the cause-specific hazards must be proportional to each other, so v i (t) is invariant to t. Then Equation 7 reduces to: lðt; xÞ=l 0 ðtÞ ¼ v 01 expðb 1 xÞ þ ð1 2 v 01 Þexpðb 2 xÞ : [8] noncancer mortality (SDHR, 3.07; 95% CI, 2.77 to 3.41; P , .001). With the Cox model of cancer-specific mortality, an increasing risk score was associated with increased cancer-specific mortality (SDHR, 2.62; 95% CI, 2.25 to 3.04; P , .001), second cancer mortality (SDHR, 1.18; 95% CI, 1.06 to 1.31; P , .001), and noncancer mortality (SDHR 1.54; 95% CI, 1.44 to 1.65; P , .001). When the Cox model of all-cause mortality was validated in patients with HNC, an increasing risk score was associated with increased cancer-specific mortality (SDHR, 2.12; 95% CI, 1.91 to 2.34; P , .001), second cancer mortality (SDHR, 1.38; 95% CI, 1.23 to 1.56; P , .001), and noncancer mortality (SDHR, 1.46; 95% CI, 1.32 to 1.62; P , .001). With the Cox model of cancerspecific mortality, an increasing risk score was associated with increased cancer-specific mortality (SDHR, 2.11; 95% CI, 1.93 to 2.31; P ,.001), second cancer mortality (SDHR, 1.37; 95% CI, 1.24 to 1.52; P ,.001), and noncancer mortality (SDHR, 1.13; 95% CI, 1.03 to 1.23; P = .19) .
When the Cox model of all-cause mortality was validated in patients with breast cancer, an increasing risk score was associated with increased cancer-specific mortality (SDHR, 2.19; 95% CI, 2.00 to 2.40; P , .001), second cancer mortality (SDHR, 1.60; 95% CI, 1.45 to 1.77; P , .001), and noncancer mortality (SDHR, 2.72; 95% CI, 2.55 to 2.89; P , .001). With the Cox model of cancerspecific mortality, an increasing risk score was associated with increased cancer-specific mortality (SDHR, 2.44; 95% CI, 2.24 to 2.65; P ,.001), second cancer mortality (SDHR, 1.36; 95% CI, 1.24 to 1.50; P ,.001), and noncancer mortality (SDHR, 1.83; 95% CI, 1.74 to 1.92; P , .001). 
